AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KRRO

Lynx1 Capital Management LP (Nichols Weston) purchased $885K of KRRO (indirect holdings)

Lynx1 Capital Management LP purchased 79,809 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $11.09 ($9.68–$12.11, $0.88M total) across 4 trades over 2026-10-22 to 2026-10-26. Filed jointly with Nichols Weston (10% owner).

Original reporting
SEC EDGAR · Lynx1 Capital Management LP, Nichols Weston
Published Oct 26, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KRRO
Bullish
high confidence
Mentioned
$KRRO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRROBullishLow
01

Why it matters

The insider buy may be interpreted as a vote of confidence, modestly supporting KRRO's price.

02

Market read

Small but notable insider purchase; limited immediate market impact.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 6/10Novelty 5/10Timing: after-hours filing on 2026-10-26

Background

Form 4 filings disclose insider transactions; this filing reports a $0.88M purchase by a 10% owner.

Company-level read

Ticker impact

$KRROBullishHigh confidence
Context

Lynx1 Capital Management LP bought 79,809 shares of Korro Bio, increasing its stake to 1,624,789 shares.

Expected impact

potential upward pressure as the market prices in the insider buy

Evidence & confidence

Insider purchases, especially by a significant owner, are typically viewed as bullish and can trigger short-term buying.

Market effects

Sector

Minor impact on the biotech sector; insider buying may be noted by sector investors.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The purchase could be a strategic move unrelated to fundamentals, and the stock may still face downside pressure.

Key entities

  • Investor
    Lynx1 Capital Management LP

    10% owner of KRRO making an open-market purchase.

  • Company
    Korro Bio, Inc.

    Biotech firm whose shares were purchased.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KRRO insider trading history →

Related articles

$KRROMedAI 8/10

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency • Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating function

SEC EDGAR 8-K
$KRROMedAI 8/10

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.

investing.com